T3期喉癌放化疗与初次手术的国际回顾性比较研究
该回顾性研究比较了两个平行连续队列:意大利博洛尼亚Sant'Orsola医院手术组与法国马赛Conception医院放化疗组,共纳入106例T3期喉癌患者(放化疗66例,手术40例)。Kaplan-Meier分析显示2年和5年无病生存率放化疗组为75%和70%,手术组均为85%(p=0.22);调整随访时间、年龄、性别和cN分期后,Cox回归显示无病生存(p=0.46)、总生存(p=0.36)和疾病特异性生存(p=0.95)均无显著差异。手术组气管造口依赖率更高(62.5% vs. 30.30%,p=0.002),胃造瘘依赖率无差异。结论认为手术与非手术方法肿瘤学结果相当,非手术组气管造口依赖率更低。
要点
- T3期喉癌放化疗与手术的肿瘤学生存结果无显著差异。
- 手术组气管造口依赖率显著高于放化疗组(62.5% vs. 30.30%)。
- 两组胃造瘘依赖率无差异。
核心结论
- 手术与放化疗治疗T3期喉癌的肿瘤学结局相当,非手术组气管造口依赖率更低。
研究设计与样本
- 国际回顾性研究,比较两个平行连续患者队列:意大利博洛尼亚Sant'Orsola医院手术组和法国马赛Conception医院放化疗组,共纳入106例T3期喉癌患者(放化疗66例,手术40例)。
主要发现
- Kaplan-Meier分析2年和5年无病生存率:放化疗组分别为75%和70%,手术组均为85%(p=0.22)。
- Cox回归调整随访时间、年龄、性别和cN分期后,无病生存(p=0.46)、总生存(p=0.36)和疾病特异性生存(p=0.95)均无显著差异。
- 手术组气管造口依赖率为62.5%,放化疗组为30.30%(p=0.002);胃造瘘依赖率无差异。
临床怎么用
- 对于T3期喉癌,放化疗可作为手术的替代方案,两者肿瘤学结局相当,且放化疗可降低气管造口依赖率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few studies have compared chemoradiotherapy with primary surgery for T3 laryngeal cancers. METHODS: This retrospective study compared two parallel consecutive patient cohorts: one treated surgically at the Sant'Orsola Hospital (Bologna, Italy) and the other managed with chemoradiotherapy at the Conception Hospital (Marseille, France). RESULTS: The study included 106 patients, 66 treated with chemoradiotherapy and 40 managed surgically. In Kaplan-Meier analysis, 2- and 5-year disease-free survival rates were 75% and 70% in the chemoradiotherapy group versus 85% at both time points in the surgery group (p = 0.22). Cox regression, adjusted for follow-up, age, sex, and cN stage, showed no significant differences in disease-free (p = 0.46), overall (p = 0.36), or disease-specific survival (p = 0.95). Tracheostomy dependence was higher after surgery (62.5% vs. 30.30%, p = 0.002), with no difference in gastrostomy dependence. CONCLUSIONS: Surgical and nonsurgical approaches achieved comparable oncologic outcomes with a lower rate of tracheostomy dependence in the nonsurgical group.
引用
- Marrè P, Fermi M, Esposti AD, et al. An International Retrospective Study Comparing Chemoradiotherapy and Primary Surgery for T3 Laryngeal Cancers. Head Neck. 2026. PMID: 41795155. doi:10.1002/hed.70225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。